Perspectives on new biomarkers in gastric cancer: Diagnostic and prognostic applications

World Journal of Gastroenterology

Volumn 20, Issue 33, 2014, Pages 11574-11585

  Pinheiro, Danilo Do Rosário ^a,b   Ferreira, Wallax Augusto Silva ^b   Barros, Mariceli Baia Leão ^b   Araújo, Mariana Diniz ^b   Rodrigues Antunes, Symara ^b   Borges, Bárbara Do Nascimento ^a,b  

^a Federal Rural University of Amazonia UFRA   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Diagnosis; Epigenetic; Gastric tumors; Genetic; Molecular markers; Prognosis; Proteomic

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATR PROTEIN; BLOOM SYNDROME HELICASE; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASPASE 5; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; FIZZY RELATED PROTEIN; HYALURONIC ACID; MICRORNA 146A; MRE11 PROTEIN; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 10; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P16; RAD50 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; SOMATOMEDIN B RECEPTOR; SYNAPSIN II; THYMOSIN BETA4; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR MARKER; UBIQUINOL CYTOCHROME C REDUCTASE; UVOMORULIN;

AGING; ALLELE; APOPTOSIS; BETA CHAIN; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CELL ADHESION; CELL CYCLE REGULATION; CELL POLARITY; CHROMOSOMAL INSTABILITY; CHROMOSOME 17Q; CHROMOSOME 18Q; CHROMOSOME 20P; CHROMOSOME 20Q; CHROMOSOME 21Q; CHROMOSOME 22Q; CHROMOSOME 4Q; CHROMOSOME 5P; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME LOSS; DELAYED DIAGNOSIS; DNA METHYLATION; DNA POLYMORPHISM; DNA REPAIR; DOWN REGULATION; ENVIRONMENTAL FACTOR; EPIGENETICS; ETHNICITY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOME IMPRINTING; GENOMIC INSTABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; MORPHOGENESIS; ONCOGENE MYC; PHENOTYPE; PRIMARY TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN POLYMORPHISM; PROTEOMICS; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; TISSUE SPECIFICITY; TUMOR INVASION; ANIMAL; BLOOD; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR; STOMACH NEOPLASMS;

ANIMALS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; RISK FACTORS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84909596044     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i33.11574     Document Type: Review

References (176)

1. González CA, Sala N, Rokkas T. Gastric cancer: epidemiologic aspects. Helicobacter 2013; 18 Suppl 1: 34-38 [PMID: 24011243 DOI: 10.1111/hel.12082]
2. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10: 643-655 [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170]
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
4. Figueiredo C, Garcia-Gonzalez MA, Machado JC. Molecular pathogenesis of gastric cancer. Helicobacter 2013; 18 Suppl 1: 28-33 [PMID: 24011242 DOI: 10.1111/hel.12083]
5. Akhavan-Niaki H, Samadani AA. Molecular insight in gastric cancer induction: an overview of cancer stemness genes. Cell Biochem Biophys 2014; 68: 463-473 [PMID: 24078401 DOI: 10.1007/s12013-013-9749-7]
6. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]
7. Hu Y, Fang JY, Xiao SD. Can the incidence of gastric cancer be reduced in the new century? J Dig Dis 2013; 14: 11-15 [PMID: 23134264 DOI: 10.1111/j.1751-2980.2012.00647.x]
8. Mahar AL, Coburn NG, Singh S, Law C, Helyer LK. A systematic review of surgery for non-curative gastric cancer. Gastric Cancer 2012; 15 Suppl 1: S125-S137 [PMID: 22033891]
9. Arigami T, Uenosono Y, Yanagita S, Nakajo A, Ishigami S, Okumura H, Kijima Y, Ueno S, Natsugoe S. Clinical significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol 2013; 20: 515-521 [PMID: 22546997 DOI: 10.1245/s10434-012-2355-x]
10. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, Print C. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2010; 2: 125-148 [PMID: 21789130 DOI: 10.1177/1758834009360519]
11. Rose-James A, Sreelekha TT. Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. Lung Cancer Inter 2012; 2012: ID 729532 [DOI: 10.1155/2012/729532]
12. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2: 210-219 [PMID: 11990857]
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
14. Leite M, Corso G, Sousa S, Milanezi F, Afonso LP, Henrique R, Soares JM, Castedo S, Carneiro F, Roviello F, Oliveira C, Seruca R. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer 2011; 128: 1606-1613 [PMID: 20533283 DOI: 10.1002/ijc.25495]
15. Nobili S, Bruno L, Landini I, Napoli C, Bechi P, Tonelli F, Rubio CA, Mini E, Nesi G. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 2011; 17: 290-299 [PMID: 21253387 DOI: 10.3748/wjg.v17.i3.290]
16. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009; 126: 615-628 [PMID: 19657673 DOI: 10.1007/s00439-009-0722-x]
17. Resende C, Ristimäki A, Machado JC. Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 2010; 15 Suppl 1: 34-39 [PMID: 21054651 DOI: 10.1111/j.1523-5378.2010.00782.x]
18. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424: 53-65 [PMID: 23669186 DOI: 10.1016/j.cca.2013.05.002]
19. Kim KJ, Lee TH, Cho NY, Yang HK, Kim WH, Kang GH. Differential clinicopathologic features in microsatellite-unstable gastric cancers with and without MLH1 methylation. Hum Pathol 2013; 44: 1055-1064 [PMID: 23266441 DOI: 10.1016/j.humpath.2012.09.009]
20. Yamashita K, Arimura Y, Saito M, Suzuki H, Furuhata T, Hirata K, Shinomura Y. Gastric cancers with microsatellite instability sharing clinical features, chemoresistance and germline MSH6 variants. Clin J Gastroenterol 2013; 6: 122-126 [DOI: 10.1007/s12328-013-0376-z]
21. An JY, Kim H, Cheong JH, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012; 131: 505-511 [PMID: 21898388 DOI: 10.1002/ijc.26399]
22. Yashiro M, Inoue T, Nishioka N, Matsuoka T, Boland CR, Hirakawa K. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma. Ann Surg Oncol 2009; 16: 2926-2935 [PMID: 19597886 DOI: 10.1245/s10434-009-0590-6]
23. Fang WL, Chang SC, Lan YT, Huang KH, Chen JH, Lo SS, Hsieh MC, Li AF, Wu CW, Chiou SH. Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg 2012; 36: 2131-2138 [PMID: 22669398 DOI: 10.1007/s00268-012-1652-7]
24. Kim H, An JY, Noh SH, Shin SK, Lee YC, Kim H. High microsatellite instability predicts good prognosis in intestinaltype gastric cancers. J Gastroenterol Hepatol 2011; 26: 585-592 [PMID: 21332554 DOI: 10.1111/j.1440-1746.2010.06487.x]
25. Jahng J, Youn YH, Kim KH, Yu J, Lee YC, Hyung WJ, Noh SH, Kim H, Kim H, Park H, Lee SI. Endoscopic and clinicopathologic characteristics of early gastric cancer with high microsatellite instability. World J Gastroenterol 2012; 18: 3571-3577 [PMID: 22826622 DOI: 10.3748/wjg.v18.i27.3571]
26. Hudler P. Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012; 2012: 761909 [PMID: 22606061 DOI: 10.1100/2012/761909]
27. Buffart TE, Louw M, van Grieken NC, Tijssen M, Carvalho B, Ylstra B, Grabsch H, Mulder CJ, van de Velde CJ, van der Merwe SW, Meijer GA. Gastric cancers of Western European and African patients show different patterns of genomic instability. BMC Med Genomics 2011; 4: 7 [PMID: 21226972 DOI: 10.1186/1755-8794-4-7]
28. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, Bazan V, Russo A. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006; 17 Suppl 7: vii97-vi102 [PMID: 16760303]
29. Martin SA, Hewish M, Lord CJ, Ashworth A. Genomic instability and the selection of treatments for cancer. J Pathol 2010; 220: 281-289 [PMID: 19890832 DOI: 10.1002/path.2631]
30. Kawauchi S, Furuay T, Uchiyama T, Adachi A, Okada T, Nakao M, Oga A, Uchida K, Sasaki K. Genomic instability and DNA ploidy are linked to DNA copy number aberrations of 8p23 and 22q11.23 in gastric cancers. Int J Mol Med 2010; 26: 333-339 [PMID: 20664948]
31. Takeno SS, Leal MF, Lisboa LC, Lipay MV, Khayat AS, Assumpc¸ão PP, Burbano RR, Smith Mde A. Genomic alterations in diffuse-type gastric cancer as shown by high-resolution comparative genomic hybridization. Cancer Genet Cytogenet 2009; 190: 1-7 [PMID: 19264226 DOI: 10.1016/j.cancergencyto.2008.09.007]
32. Fan B, Dachrut S, Coral H, Yuen ST, Chu KM, Law S, Zhang L, Ji J, Leung SY, Chen X. Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. PLoS One 2012; 7: e29824 [PMID: 22539939 DOI: 10.1371/journal.pone.0029824]
33. Rossi E, Klersy C, Manca R, Zuffardi O, Solcia E. Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. Hum Pathol 2011; 42: 1937-1945 [PMID: 21676433 DOI: 10.1016/j.humpath.2011.02.016]
34. Kulig J, Kolodziejczyk P, Kulig P, Legutko J. Targeted therapy for gastric cancer - current status. J Oncol Pharm Pract 2013; 19: 75-81 [PMID: 22711713 DOI: 10.1177/1078155212449030]
35. Fisher SB, Fisher KE, Squires MH, Patel SH, Kooby DA, El-Rayes BF, Cardona K, Russell MC, Staley CA, Farris AB, Maithel SK. HER2 in resected gastric cancer: Is there prognostic value? J Surg Oncol 2014; 109: 61-66 [PMID: 24122802 DOI: 10.1002/jso.23456]
36. Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer 2014; 17: 34-42 [PMID: 23430266 DOI: 10.1007/s10120-013-0239-9]
37. Oh HS, Eom DW, Kang GH, Ahn YC, Lee SJ, Kim JH, Jang HJ, Kim EJ, Oh KH, Ahn HJ. Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer 2014; 17: 402-411 [PMID: 23955257]
38. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013; 19: 2171-2178 [PMID: 23599643 DOI: 10.3748/wjg.v19.i14.2171]
39. Bədescu A, Georgescu CV, Vere CC, Crəit¸oiu S, Grigore D. Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. Rom J Morphol Embryol 2012; 53: 997-1005 [PMID: 23303024]
40. Jácome AA, Wohnrath DR, Scapulatempo Neto C, Carneseca EC, Serrano SV, Viana LS, Nunes JS, Martinez EZ, Santos JS. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer 2014; 17: 76-86 [PMID: 23455716 DOI: 10.1007/s10120-013-0236-z]
41. Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol 2012; 13: 377-389 [PMID: 22552927 DOI: 10.1007/s11864-012-0192-6]
42. Kochi M, Fujii M, Masuda S, Kanamori N, Mihara Y, Funada T, Tamegai H, Watanabe M, Suda H, Takayama T. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol 2013; 8: 191 [PMID: 24261710]
43. Qiu MZ, Li Q, Wang ZQ, Liu TS, Liu Q, Wei XL, Jin Y, Wang DS, Ren C, Bai L, Zhang DS, Wang FH, Li YH, Xu RH. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. Int J Cancer 2014; 134: 2468-2477 [PMID: 24155030 DOI: 10.1002/ijc.28559]
44. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 2013; 31: 4445-4452 [PMID: 24127447 DOI: 10.1200/JCO.2013.48.9070]
45. Ding X, Qu X, Fan Y, Che X, Qu J, Xu L, Liu J, Liu Y. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells. Anticancer Drugs 2014; 25: 315-322 [PMID: 24300914 DOI: 10.1097/CAD.0000000000000048]
46. Xu AG, Li SG, Liu JH, Gan AH. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol 2001; 7: 403-406 [PMID: 11819799]
47. Ishii HH, Gobé GC, Pan W, Yoneyama J, Ebihara Y. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol 2002; 17: 966-972 [PMID: 12167117]
48. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC, Luo J. Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: association with Helicobactor pylori cagA (+) infection. World J Gastroenterol 2004; 10: 491-496 [PMID: 14966904]
49. Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimäki A, Offerhaus GJ. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 2006; 19: 564-572 [PMID: 16474375]
50. Lima VP, de Lima MA, André AR, Ferreira MV, Barros MA, Rabenhorst SH. H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression. World J Gastroenterol 2008; 14: 884-891 [PMID: 18240345]
51. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol 2008; 14: 5962-5968 [PMID: 18932273]
52. de Souza CR, Leal MF, Calcagno DQ, Costa Sozinho EK, Borges Bdo N, Montenegro RC, Dos Santos AK, Dos Santos SE, Ribeiro HF, Assumpc¸ão PP, de Arruda Cardoso Smith M, Burbano RR. MYC deregulation in gastric cancer and its clinicopathological implications. PLoS One 2013; 8: e64420 [PMID: 23717612 DOI: 10.1371/journal.pone.0064420]
53. Bellini MF, Cadamuro AC, Succi M, Proenc¸a MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012; 2012: 891961 [PMID: 22919278 DOI: 10.1155/2012/891961]
54. Carneiro P, Fernandes MS, Figueiredo J, Caldeira J, Carvalho J, Pinheiro H, Leite M, Melo S, Oliveira P, Simões-Correia J, Oliveira MJ, Carneiro F, Figueiredo C, Paredes J, Oliveira C, Seruca R. E-cadherin dysfunction in gastric cancer - cellular consequences, clinical applications and open questions. FEBS Lett 2012; 586: 2981-2989 [PMID: 22841718 DOI: 10.1016/j.febslet.2012.07.045]
55. Corso G, Marrelli D, Pascale V, Vindigni C, Roviello F. Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer 2012; 12: 8 [PMID: 22225527 DOI: 10.1186/1471-2407-12-8]
56. Bag A, Jyala NS, Bag N. Indian studies on genetic polymorphisms and cancer risk. Indian J Cancer 2012; 49: 144-162 [PMID: 22842182 DOI: 10.4103/0019-509X.98941]
57. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002; 123: 1793-1803 [PMID: 12454835]
58. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186 [PMID: 12374879]
59. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1604-1617 [PMID: 20880168 DOI: 10.1111/j.1440-1746.2010.06428.x]
60. Loh M, Koh KX, Yeo BH, Song CM, Chia KS, Zhu F, Yeoh KG, Hill J, Iacopetta B, Soong R. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer 2009; 45: 2562-2568 [PMID: 19375306 DOI: 10.1016/j.ejca.2009.03.017]
61. Engin AB, Karahalil B, Karakaya AE, Engin A. Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arh Hig Rada Toksikol 2011; 62: 207-214 [PMID: 21971103 DOI: 10.2478/10004-1254-62-2011-2098]
62. Kim N, Cho SI, Lee HS, Park JH, Kim JH, Kim JS, Jung HC, Song IS. The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci 2010; 55: 101-110 [PMID: 19184427 DOI: 10.1007/s10620-008-0688-x]
63. Liu KJ, Qi HZ, Yao HL, Lei SL, Lei ZD, Li TG, Zhao H. An updated meta-analysis of the p53 codon 72 polymorphism and gastric cancer risk. Mol Biol Rep 2012; 39: 8265-8275 [PMID: 22707142 DOI: 10.1007/s11033-012-1674-0]
64. Gao L, Nieters A, Brenner H. Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet 2009; 17: 1658-1667 [PMID: 19536170 DOI: 10.1038/ejhg.2009.102]
65. Zhang Q, Ma YY, Wang HJ, Shao CM, Zhang J, Ye ZY. Meta-analysis of the association between P53 codon 72 polymorphisms and gastric cancer. J Surg Oncol 2013; 107: 360-366 [PMID: 22886602 DOI: 10.1002/jso.23233]
66. Su XL, Jin JJ. Pro variant of TP53 Arg72Pro contributes to gastric cancer risk in Asians: evidence from a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 915-921 [PMID: 22631671]
67. Xiang B, Mi YY, Li TF, Liu PF. Updated meta-analysis of the TP53 Arg72Pro polymorphism and gastric cancer risk. Asian Pac J Cancer Prev 2012; 13: 1787-1791 [PMID: 22901123]
68. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer 2011; 129: 920-930 [PMID: 20886596 DOI: 10.1002/ijc.25710]
69. Wang S, Chen L, Zhao Q, Rong H, Wang M, Gong W, Zhou J, Wu D, Zhang Z. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy. Cancer Chemother Pharmacol 2013; 71: 1073-1082 [PMID: 23423487 DOI: 10.1007/s00280-013-2103-3]
70. Huang ZH, Hua D, Li LH, Zhu JD. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol 2008; 134: 1129-1134 [PMID: 18357466 DOI: 10.1007/s00432-008-0380-8]
71. Huang ZH, Hua D, Du X. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 2009; 64: 1001-1007 [PMID: 19247656 DOI: 10.1007/s00280-009-0956-2]
72. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Lee WS, Sohn CH, Jung JS, Kim GC, Chung HY, Yu W. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 2009; 64: 355-360 [PMID: 19052714 DOI: 10.1007/s00280-008-0879-3]
73. Chen B, Zhou Y, Yang P, Liu L, Qin XP, Wu XT. CDH1-160C& gt; A gene polymorphism is an ethnicity-dependent risk factor for gastric cancer. Cytokine 2011; 55: 266-273 [PMID: 21570316 DOI: 10.1016/j.cyto.2011.04.008]
74. Al-Moundhri MS, Al-Khanbashi M, Al-Kindi M, Al-Nabhani M, Burney IA, Al-Farsi A, Al-Bahrani B. Association of E-cadherin (CDH1) gene polymorphisms and gastric cancer risk. World J Gastroenterol 2010; 16: 3432-3436 [PMID: 20632448]
75. Li YL, Tian Z, Zhang JB, Fu BY. CDH1 promoter polymorphism and stomach cancer susceptibility. Mol Biol Rep 2012; 39: 1283-1286 [PMID: 21625863 DOI: 10.1007/s11033-011-0860-9]
76. Gao L, Nieters A, Brenner H. Meta-analysis: tumour invasion-related genetic polymorphisms and gastric cancer susceptibility. Aliment Pharmacol Ther 2008; 28: 565-573 [PMID: 18544073 DOI: 10.1111/j.1365-2036.2008.03760.x]
77. Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, Nojima D, Carroll P, Dahiya R. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 2000; 60: 873-876 [PMID: 10706097]
78. Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, Spain S, Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington SM, Tenesa A, Prendergast JG, Barnetson RA, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop DT, Gray R, Maher ER, Lucassen A, Kerr D, Evans DG, Schafmayer C, Buch S, Völzke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen JT, Hopper JL, Southey MC, Giles GG, Severi G, Castellví-Bel S, Ruiz-Ponte C, Carracedo A, Castells A, Försti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, Ho JW, Cheng KK, Sham PC, Luk J, Agúndez JA, Ladero JM, de la Hoya M, Caldés T, Niittymäki I, Tuupanen S, Karhu A, Aaltonen L, Cazier JB, Campbell H, Dunlop MG, Houlston RS. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008; 40: 623-630 [PMID: 18372905 DOI: 10.1038/ng.111]
79. Pharoah PD, Oliveira C, Machado JC, Keller G, Vogelsang H, Laux H, Becker KF, Hahn H, Paproski SM, Brown LA, Caldas C, Huntsman D. CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer 2002; 101: 196-197 [PMID: 12209998]
80. Kuraoka K, Oue N, Yokozaki H, Kitadai Y, Ito R, Nakayama H, Yasui W. Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. Int J Oncol 2003; 23: 421-427 [PMID: 12851691]
81. Lu Y, Xu YC, Shen J, Yu RB, Niu JY, Guo JT, Hu X, Shen HB. E-cadherin gene C-160A promoter polymorphism and risk of non-cardia gastric cancer in a Chinese population. World J Gastroenterol 2005; 11: 56-60 [PMID: 15609397]
82. Medina-Franco H, Ramos-De la Medina A, Vizcaino G, Medina-Franco JL. Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population. Ann Surg Oncol 2007; 14: 2246-2249 [PMID: 17549573]
83. Borges Bdo N, Santos Eda S, Bastos CE, Pinto LC, Anselmo NP, Quaresma JA, Calcagno DQ, Burbano RM, Harada ML. Promoter polymorphisms and methylation of E-cadherin (CDH1) and KIT in gastric cancer patients from northern Brazil. Anticancer Res 2010; 30: 2225-2233 [PMID: 20651373]
84. Zhan Z, Wu J, Zhang JF, Yang YP, Tong S, Zhang CB, Li J, Yang XW, Dong W. CDH1 gene polymorphisms, plasma CDH1 levels and risk of gastric cancer in a Chinese population. Mol Biol Rep 2012; 39: 8107-8113 [PMID: 22535324 DOI: 10.1007/s11033-012-1658-0]
85. Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW. The E-cadherin gene polymorphism 160C-& gt; A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol 2008; 167: 7-14 [PMID: 17971340]
86. Cui Y, Xue H, Lin B, Ni P, Fang JY. A meta-analysis of CDH1 C-160A genetic polymorphism and gastric cancer risk. DNA Cell Biol 2011; 30: 937-945 [PMID: 21612411 DOI: 10.1089/dna.2011.1257]
87. Zhang XF, Wang YM, Ge H, Cao YY, Chen ZF, Wen DG, Guo W, Wang N, Li Y, Zhang JH. Association of CDH1 single nucleotide polymorphisms with susceptibility to esophageal squamous cell carcinomas and gastric cardia carcinomas. Dis Esophagus 2008; 21: 21-29 [PMID: 18197935 DOI: 10.1111/j.1442-2050.2007.00724.x]
88. Yamada H, Shinmura K, Ikeda S, Tao H, Otani T, Hanaoka T, Tsuneyoshi T, Tsugane S, Sugimura H. Association between CDH1 haplotypes and gastric cancer risk in a Japanese population. Scand J Gastroenterol 2007; 42: 1479-1485 [PMID: 17852867]
89. Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo AM, Magnani M, Toro T, Burchill T, Futschik ME, Merriman T, Guilford P. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 2002; 21: 8192-8195 [PMID: 12444556]
90. Pan F, Tian J, Zhang Y, Pan YY. CDH1 -160C& gt; A gene polymorphism is an ethnicity-dependent risk factor for gastric cancer. Cytokine 2012; 59: 20-21 [PMID: 22575615 DOI: 10.1016/j.cyto.2012.04.028]
91. Uppal DS, Powell SM. Genetics/genomics/proteomics of gastric adenocarcinoma. Gastroenterol Clin North Am 2013; 42: 241-260 [PMID: 23639639]
92. Yang J, Song YC, Dang CX, Song TS, Liu ZG, Guo YM, Li ZF, Huang C. Serum peptidome profiling in patients with gastric cancer. Clin Exp Med 2012; 12: 79-87 [PMID: 21739109 DOI: 10.1007/s10238-011-0149-2]
93. Liu W, Liu B, Cai Q, Li J, Chen X, Zhu Z. Proteomic identification of serum biomarkers for gastric cancer using multidimensional liquid chromatography and 2D differential gel electrophoresis. Clin Chim Acta 2012; 413: 1098-1106 [PMID: 22446497 DOI: 10.1016/j.cca.2012.03.003]
94. He CZ, Zhang KH, Li Q, Liu XH, Hong Y, Lv NH. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol 2013; 13: 87 [PMID: 23672279 DOI: 10.1186/1471-230X-13-87]
95. Lee JC, Lee SY, Kim CY, Yang DH. Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer. J Korean Surg Soc 2013; 85: 283-289 [PMID: 24368986 DOI: 10.4174/jkss.2013.85.6.283]
96. Bagaria B, Sood S, Sharma R, Lalwani S. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med 2013; 10: 148-157 [PMID: 24379990 DOI: 10.7497/j.issn.2095-3941.2013.03.005]
97. Huang L, Xu A, Li T, Han W, Wu S, Wang Y. Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances. Med Oncol 2013; 30: 651 [PMID: 23820956 DOI: 10.1007/s12032-013-0651-3]
98. Xiao Y, Zhang J, He X, Ji J, Wang G. Diagnostic values of carcinoembryonic antigen in predicting peritoneal recurrence after curative resection of gastric cancer: a meta-analysis. Ir J Med Sci 2013; Epub ahead of print [PMID: 24378872]
99. Takata A, Kurokawa Y, Fujiwara Y, Nakamura Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M, Doki Y. Prognostic value of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer. World J Surg 2014; 38: 1107-1111 [PMID: 24305936 DOI: 10.1007/s00268-013-2385-y]
100. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008; 25: 1075-1084 [PMID: 18821070 DOI: 10.1007/s12325-008-0100-4]
101. Deng K, Lin S, Zhou L, Geng Q, Li Y, Xu M, Na R. Three aromatic amino acids in gastric juice as potential biomarkers for gastric malignancies. Anal Chim Acta 2011; 694: 100-107 [PMID: 21565309 DOI: 10.1016/j.aca.2011.03.053]
102. Deng K, Lin S, Zhou L, Li Y, Chen M, Wang Y, Li Y. High levels of aromatic amino acids in gastric juice during the early stages of gastric cancer progression. PLoS One 2012; 7: e49434 [PMID: 23152906 DOI: 10.1371/journal.pone.0049434]
103. Dias A, Garcia C, Majewski M, Wallner G, McCallum RW, Poplawski C, Sarosiek J. Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study. Dig Dis Sci 2011; 56: 3220-3225 [PMID: 21695403 DOI: 10.1007/s10620-011-1758-z]
104. Kam SY, Hennessy T, Chua SC, Gan CS, Philp R, Hon KK, Lai L, Chan WH, Ong HS, Wong WK, Lim KH, Ling KL, Tan HS, Tan MM, Ho M, Kon OL. Characterization of the human gastric fluid proteome reveals distinct pH-dependent protein profiles: implications for biomarker studies. J Proteome Res 2011; 10: 4535-4546 [PMID: 21842849 DOI: 10.1021/pr200349z]
105. Ruan HL, Hong RT, Xie HJ, Hu NZ, Xu JM, Zhang W. Significance of elevated levels of collagen type IV and hyaluronic acid in gastric juice and serum in gastric cancer and precancerous lesion. Dig Dis Sci 2011; 56: 2001-2008 [PMID: 21264511 DOI: 10.1007/s10620-011-1571-8]
106. Wu W, Juan WC, Liang CR, Yeoh KG, So J, Chung MC. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin Appl 2012; 6: 152-162 [PMID: 22532451 DOI: 10.1002/prca.201100050]
107. Wu W, Chung MC. The gastric fluid proteome as a potential source of gastric cancer biomarkers. J Proteomics 2013; 90: 3-13 [PMID: 23665003 DOI: 10.1016/j.jprot.2013.04.035]
108. Cheng Y, Zhang J, Li Y, Wang Y, Gong J. Proteome analysis of human gastric cardia adenocarcinoma by laser capture microdissection. BMC Cancer 2007; 7: 191 [PMID: 17927838 DOI: 10.1186/1471-2407-7-191]
109. Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, Caprioli RM, Green JE. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010; 9: 4123-4130 [PMID: 20557134 DOI: 10.1021/pr100302b]
110. Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics 2012; 75: 3081-3097 [PMID: 22498886 DOI: 10.1016/j.jprot.2012.03.046]
111. Sousa JF, Ham AJ, Whitwell C, Nam KT, Lee HJ, Yang HK, Kim WH, Zhang B, Li M, LaFleur B, Liebler DC, Goldenring JR. Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am J Pathol 2012; 181: 1560-1572 [PMID: 22944598 DOI: 10.1016/j.ajpath.2012.07.027]
112. Balluff B, Rauser S, Meding S, Elsner M, Schöne C, Feuchtinger A, Schuhmacher C, Novotny A, Jütting U, Maccarrone G, Sarioglu H, Ueffing M, Braselmann H, Zitzelsberger H, Schmid RM, Höfler H, Ebert MP, Walch A. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 2011; 179: 2720-2729 [PMID: 22015459 DOI: 10.1016/j.ajpath.2011.08.032]
113. Mohri Y, Mohri T, Wei W, Qi YJ, Martin A, Miki C, Kusunoki M, Ward DG, Johnson PJ. Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br J Cancer 2009; 101: 295-302 [PMID: 19550422 DOI: 10.1038/sj.bjc.6605138]
114. Uen YH, Lin KY, Sun DP, Liao CC, Hsieh MS, Huang YK, Chen YW, Huang PH, Chen WJ, Tai CC, Lee KW, Chen YC, Lin CY. Comparative proteomics, network analysis and posttranslational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer. J Proteomics 2013; 83: 197-213 [PMID: 23541716 DOI: 10.1016/j.jprot.2013.03.007]
115. Bones J, Mittermayr S, O'Donoghue N, Guttman A, Rudd PM. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem 2010; 82: 10208-10215 [PMID: 21073175 DOI: 10.1021/ac102860w]
116. Bones J, Byrne JC, O'Donoghue N, McManus C, Scaife C, Boissin H, Nastase A, Rudd PM. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 2011; 10: 1246-1265 [PMID: 21142185 DOI: 10.1021/pr101036b]
117. Klaamas K, Kodar K, Kurtenkov O. An increased level of the Concanavalin A-positive IgG in the serum of patients with gastric cancer as evaluated by a lectin enzyme-linked immunosorbent assay (LELISA). Neoplasma 2008; 55: 143-150 [PMID: 18237253 DOI: 10.3748/wjg.v19.i23.3573]
118. Xu Y, Zhang L, Hu G. Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis. Biologicals 2009; 37: 18-25 [PMID: 18848467 DOI: 10.1016/j.biologicals.2008.08.002]
119. Li K, Sun Z, Zheng J, Lu Y, Bian Y, Ye M, Wang X, Nie Y, Zou H, Fan D. In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. J Proteomics 2013; 82: 130-140 [PMID: 23470797 DOI: 10.1016/j.jprot.2013.02.021]
120. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945 DOI: 10.1038/nrc1997]
121. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269 [PMID: 16557279 DOI: 10.1038/nrc1840]
122. Yin Y, Li J, Chen S, Zhou T, Si J. MicroRNAs as Diagnostic Biomarkers in Gastric Cancer. Int J Mol Sci 2012; 13: 12544-12555 [PMID: 23202912 DOI: 10.3390/ijms131012544]
123. Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, Zhao Z, Xu Z, El-Rifai W. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer 2013; 119: 1985-1993 [PMID: 23456798 DOI: 10.1002/cncr.28002]
124. Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17: 3976-3985 [PMID: 22046085 DOI: 10.3748/wjg.v17.i35.3976]
125. Kim BH, Hong SW, Kim A, Choi SH, Yoon SO. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol 2013; 107: 505-510 [PMID: 22996433 DOI: 10.1002/jso.23271]
126. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, Ma Y, Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012; 316: 196-203 [PMID: 22169097 DOI: 10.1016/j.canlet.2011.10.034]
127. Xu XD, He XJ, Tao HQ, Zhang W, Wang YY, Ye ZY, Zhao ZS. Abnormal expression of miR-301a in gastric cancer associated with progression and poor prognosis. J Surg Oncol 2013; 108: 197-202 [PMID: 23832550 DOI: 10.1002/jso.23374]
128. Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, Wang Y, Luo M, Zhao H, Dong L, Song W, Wang F, Wang W, Zhang J, Yu J. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis 2014; 35: 497-506 [PMID: 24130168]
129. Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 2011; 17: 4277-4284 [PMID: 21632853 DOI: 10.1158/1078-0432.CCR-10-2866]
130. Wang YY, Ye ZY, Zhao ZS, Li L, Wang YX, Tao HQ, Wang HJ, He XJ. Clinicopathologic significance of miR-10b expression in gastric carcinoma. Hum Pathol 2013; 44: 1278-1285 [PMID: 23351547 DOI: 10.1016/j.humpath.2012.10.014]
131. Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep 2012; 27: 1759-1764 [PMID: 22407237 DOI: 10.3892/or.2012.1709]
132. Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J, Liu Y, Gao Z, Li J, Shen L, Lu Y. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 2011; 22: 2257-2266 [PMID: 21343377 DOI: 10.1093/annonc/mdq758]
133. Liu K, Qian T, Tang L, Wang J, Yang H, Ren J. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 2012; 10: 225 [PMID: 23107361 DOI: 10.1186/1477-7819-10-225]
134. Liu K, Li G, Fan C, Diao Y, Wu B, Li J. Increased Expression of MicroRNA-221 in gastric cancer and its clinical significance. J Int Med Res 2012; 40: 467-474 [PMID: 22613407]
135. Tseng CW, Lin CC, Chen CN, Huang HC, Juan HF. Integrative network analysis reveals active microRNAs and their functions in gastric cancer. BMC Syst Biol 2011; 5: 99 [PMID: 21703006 DOI: 10.1186/1752-0509-5-99]
136. Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG, Liu BY. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 2012; 27: 1960-1966 [PMID: 22426647 DOI: 10.3892/or.2012.1719]
137. Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao X, Zhang X, Cui L, Ye G, Le Y, Guo J. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 2013; 30: 365 [PMID: 23307240 DOI: 10.1007/s12032-012-0365-y]
138. Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X, Lu B, Wu C, Ju J. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One 2011; 6: e23271 [PMID: 21876743 DOI: 10.1371/journal.pone.0023271]
139. Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010; 59: 579-585 [PMID: 19951901 DOI: 10.1136/gut.2008.175497]
140. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J, Quindós M, Carral A, Figueroa A, Antón-Aparicio LM, Calvo L. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012; 10: 186 [PMID: 22954417 DOI: 10.1186/1479-5876-10-186]
141. Zhang X, Cui L, Ye G, Zheng T, Song H, Xia T, Yu X, Xiao B, Le Y, Guo J. Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol 2012; 33: 2349-2355 [PMID: 22926798 DOI: 10.1007/s13277-012-0497-x]
142. Cui L, Zhang X, Ye G, Zheng T, Song H, Deng H, Xiao B, Xia T, Yu X, Le Y, Guo J. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer 2013; 119: 1618-1626 [PMID: 23335180 DOI: 10.1002/cncr.27903]
143. Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, Chen F, Zheng G. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One 2012; 7: e40037 [PMID: 22802949 DOI: 10.1371/journal.pone.0040037]
144. Song MY, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, Yuasa Y, Kang D, Kim YS, You WC. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 2012; 7: e33608 [PMID: 22432036 DOI: 10.1371/journal.pone.0033608]
145. Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, Zhu ZG. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol 2013; 20 Suppl 3: S397-S405 [PMID: 22956063 DOI: 10.1245/s10434-012-2600-3]
146. Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013; 434: 688-694 [PMID: 23603256 DOI: 10.1016/j.bbrc.2013.04.010]
147. Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013; 587: 3069-3075 [PMID: 23932924 DOI: 10.1016/j.febslet.2013.06.058]
148. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr 2012; 3: 21-38 [PMID: 22332098 DOI: 10.3945/an.111.000992]
149. Auclair G, Weber M. Mechanisms of DNA methylation and demethylation in mammals. Biochimie 2012; 94: 2202-2211 [PMID: 22634371 DOI: 10.1016/j.biochi.2012.05.016]
150. Lewin J, Schmitt AO, Adorján P, Hildmann T, Piepenbrock C. Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates. Bioinformatics 2004; 20: 3005-3012 [PMID: 15247106 DOI: 10.1093/bioinformatics/bth346]
151. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005; 96: 206-211 [PMID: 15819717 DOI: 10.1111/j.1349-7006.2005.00035.x]
152. Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 2007; 211: 287-295 [PMID: 17238139 DOI: 10.1002/jcp.20982]
153. Shin SH, Park SY, Ko JS, Kim N, Kang GH. Aberrant CpG island hypermethylation in pediatric gastric mucosa in association with Helicobacter pylori infection. Arch Pathol Lab Med 2011; 135: 759-765 [PMID: 21631269 DOI: 10.1043/2010-0140-OA.1]
154. Du W, Wang S, Zhou Q, Li X, Chu J, Chang Z, Tao Q, Ng EK, Fang J, Sung JJ, Yu J. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene 2013; 32: 3319-3328 [PMID: 22907434 DOI: 10.1038/onc.2012.359]
155. Park SY, Kook MC, Kim YW, Cho NY, Jung N, Kwon HJ, Kim TY, Kang GH. CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch 2010; 457: 415-422 [PMID: 20737169 DOI: 10.1007/s00428-010-0962-0]]
156. Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol 2009; 40: 1534-1542 [PMID: 19695681 DOI: 10.1016/j.humpath.2009.01.029]
157. do Nascimento Borges B, Burbano RM, Harada ML. Analysis of the methylation patterns of the p16 INK4A, p15 INK4B, and APC genes in gastric adenocarcinoma patients from a Brazilian population. Tumour Biol 2013; 34: 2127-2133 [PMID: 23504555 DOI: 10.1007/s13277-013-0742-y]
158. Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, Miyazaki K. Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J Gastroenterol 2007; 42: 866-873 [PMID: 18008030 DOI: 10.1007/s00535-007-2113-1]
159. Shi J, Zhang G, Yao D, Liu W, Wang N, Ji M, He N, Shi B, Hou P. Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res 2012; 2: 116-129 [PMID: 22206050]
160. Hiraki M, Kitajima Y, Sato S, Mitsuno M, Koga Y, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K. Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer. Ann Surg Oncol 2010; 17: 1177-1186 [PMID: 19957042 DOI: 10.1245/s10434-009-0815-8]
161. Guo W, Dong Z, Guo Y, Lin X, Chen Z, Kuang G, Yang Z. Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma. Clin Exp Metastasis 2013; 30: 265-275 [PMID: 22983529 DOI: 10.1007/s10585-012-9533-x]
162. Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S, Wu YC. Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. PLoS One 2013; 8: e67195 [PMID: 23826230 DOI: 10.1371/journal.pone.0067195]
163. Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q, Jin H, Zeng Z, Sung JJ, Yu J. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut 2012; 61: 977-985 [PMID: 21917650 DOI: 10.1136/gutjnl-2011-300411]
164. Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, Kao HW, Fang WL, Huang KH, Chan WC, Lin WC. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 2011; 129: 2600-2610 [PMID: 21960261 DOI: 10.1002/ijc.25919]
165. Wang L, Chen S, Xue M, Zhong J, Wang X, Gan L, Lam EK, Liu X, Zhang J, Zhou T, Yu J, Jin H, Si J. Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis. Mol Med 2012; 18: 389-400 [PMID: 22160393 DOI: 10.2119/molmed.2011.00172]
166. Sugita H, Iida S, Inokuchi M, Kato K, Ishiguro M, Ishikawa T, Takagi Y, Enjoji M, Yamada H, Uetake H, Kojima K, Sugihara K. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep 2011; 25: 513-518 [PMID: 21152877 DOI: 10.3892/or.2010.1085]
167. Hiraki M, Kitajima Y, Sato S, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K. Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World J Gastroenterol 2010; 16: 330-338 [PMID: 20082478 DOI: 10.3748/wjg.v16.i3.330]
168. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, Rha SY, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT, Tan P. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 2013; 62: 22-33 [PMID: 22535375 DOI: 10.1136/gutjnl-2011-301113]
169. Stənculescu D, Mərgəritescu C, Stepan A, Mitrut AO. E-cadherin in gastric carcinomas related to histological prognostic parameters. Rom J Morphol Embryol 2011; 52: 1107-1112 [PMID: 22119833]
170. Yu QM, Wang XB, Luo J, Wang S, Fang XH, Yu JL, Ling ZQ. CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol 2012; 106: 765-771 [PMID: 22514028 DOI: 10.1002/jso.23116]
171. Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 2005; 92: 2190-2194 [PMID: 15942635 DOI: 10.1038/sj.bjc.6602636]
172. Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK, Leung WK. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 2007; 97: 895-901 [PMID: 17848950 DOI: 10.1038/sj.bjc.6603968]
173. Ng EK, Leung CP, Shin VY, Wong CL, Ma ES, Jin HC, Chu KM, Kwong A. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One 2011; 6: e22233 [PMID: 21789241 DOI: 10.1371/journal.pone.0022233]
174. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 2009; 136: 2149-2158 [PMID: 19375421 DOI: 10.1053/j.gastro.2009.02.085]
175. Sudo T, Mimori K, Nishida N, Kogo R, Iwaya T, Tanaka F, Shibata K, Fujita H, Shirouzu K, Mori M. Histone deacetylase 1 expression in gastric cancer. Oncol Rep 2011; 26: 777-782 [PMID: 21725604 DOI: 10.3892/or.2011.1361]
176. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9: 139-148 [PMID: 18207460 DOI: 10.1016/S1470-2045(08)70004-4]